Aratana Therapeutics to Present at Two Upcoming Investor Conferences

KANSAS CITY, Kan. and BOSTON, Sept. 5, 2013 /PRNewswire/ -- Aratana Therapeutics (Nasdaq: PETX), a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative prescription medications for pets (pet therapeutics), today announced that it will present at the Stifel Nicolaus Healthcare Conference, to be held September 11-13, 2013, at the Four Seasons Hotel in Boston, and at the Craig-Hallum 4^th Annual Alpha Select Conference, to be held September 26, 2013, at the Convene 730 3^rd Avenue in New York.

Steven St. Peter, M.D., President and Chief Executive Officer, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conferences. 

The presentations will be webcast live and remain available for a period of two weeks following the live presentation.  To access the webcasts, please visit the investor relations section of the Aratana website at aratana.investorroom.com.

About Aratana Therapeutics
Aratana Therapeutics is a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana's strategy is to in-license proprietary compounds from human biopharmaceutical companies and to develop these product candidates into therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.  For more information, please visit www.aratana.com.

Contacts:
Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com; (212) 375-2664

Andrew Mielach (media)
amielach@tiberend.com; (212) 375-2694  

SOURCE Aratana Therapeutics